1M6MYTD1A5AMAX
Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 153,20 € (-19,33 %). La mediana es de 146,41 € (-22,90 %).
| Comprar |
8 |
| Mantener |
3 |
| Vender |
0 |
Noticias Ir al feed de noticias
Cidara Therapeutics rises to 52-week high after takeover bid from Merck
Cidara Therapeutics' stock climbed to $220.49, marking a 52-week high, driven by Merck's announcement that it intends to acquire Cidara for $221.50 per share (about $9.2 billion). At the center of the deal is the Phase‑3 drug candidate CD388 for influenza. Cidara recently reported no revenue but holds $476 million in cash; analysts mostly downgraded ratings and set price targets at the takeover offer. Data show very high annual returns (1,141.61%) and metrics suggesting overvaluation (price‑to‑book ratio 16.4). » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2025 | |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | -38,35 M | - |
| Beneficio neto | -70,93 M | - |
| EBITDA | -70,9 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 4834,86 M € |
Número de acciones | 25,36 M |
Máximo/mínimo de 52 semanas | 190,70 € - 13,11 € |
| Dividendos | No |
Beta | 1,53 |
Ratio P/E | -34,54 |
Ratio PEG | -1,17 |
Ratio P/B | 8,15 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | Cidara Therapeutics Aktie |
| CEO | Jeffrey L. Stein |
| Sede | San Diego,
ca Estados Unidos |
| Sector | Salud |
| Industria | Biotecnología |
| Empleados | 38 |
